FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Michael Fisher

Research Profile

Anatomy

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Matthew F Brown; Kevin Bahnck; Laura C Blumberg; William H Brissette; Sara A Burrell; James P Driscoll; Flavia Fedeles; Michael B Fisher; Robert S Foti; Ronald P Gladue; Aikomari Guzman-Martinez; Matthew M Hayward; Paul D Lira; Brett M Lillie; Yi Lu; Greg D Lundquist; Eric B McElroy; Molly A McGlynn; Timothy J Paradis; Christopher S Poss; James H Roache; Andrei Shavnya; Richard M Shepard; Kristen A Trevena; Laurie A Tylaska
Piperazinyl CCR1 antagonists--optimization of human liver microsome stability.
Timothy J Strelevitz; Robert S Foti; Michael B Fisher
In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance.
Sara M Skaggs; Robert S Foti; Michael B Fisher
A streamlined method to predict hepatic clearance using human liver microsomes in the presence of human plasma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Michael Fisher (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Matthew F Brown; Kevin Bahnck; Laura C Blumberg; William H Brissette; Sara A Burrell; James P Driscoll; Flavia Fedeles; Michael B Fisher; Robert S Foti; Ronald P Gladue; Aikomari Guzman-Martinez; Matthew M Hayward; Paul D Lira; Brett M Lillie; Yi Lu; Greg D Lundquist; Eric B McElroy; Molly A McGlynn; Timothy J Paradis; Christopher S Poss; James H Roache; Andrei Shavnya; Richard M Shepard; Kristen A Trevena; Laurie A Tylaska
Piperazinyl CCR1 antagonists--optimization of human liver microsome stability.
Bioorganic & medicinal chemistry letters 2007;17(11):3109-12.
2006: Timothy J Strelevitz; Robert S Foti; Michael B Fisher
In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance.
Journal of pharmaceutical sciences 2006;95(6):1334-41.
2006: Sara M Skaggs; Robert S Foti; Michael B Fisher
A streamlined method to predict hepatic clearance using human liver microsomes in the presence of human plasma.
Journal of pharmacological and toxicological methods 2006;53(3):284-90.
2005: Juntyma J Engtrakul; Robert S Foti; Timothy J Strelevitz; Michael B Fisher
Altered AZT (3'-azido-3'-deoxythymidine) glucuronidation kinetics in liver microsomes as an explanation for underprediction of in vivo clearance: comparison to hepatocytes and effect of incubation environment.
Drug metabolism and disposition: the biological fate of chemicals 2005;33(11):1621-7.
2005: Robert S Foti; Michael B Fisher
Assessment of UDP-glucuronosyltransferase catalyzed formation of ethyl glucuronide in human liver microsomes and recombinant UGTs.
Forensic science international 2005;153(2-3):109-16.
2004: Robert S Foti; Michael B Fisher
Impact of incubation conditions on bufuralol human clearance predictions: enzyme lability and nonspecific binding.
Drug metabolism and disposition: the biological fate of chemicals 2004;32(3):295-304.
2004: Robert S Foti; Michael B Fisher
Importance of patient selection when determining the significance of the CYP3A5 polymorphism in clinical trials.
The pharmacogenomics journal 2004;4(6):362-4.
2002: Michael B Fisher; Kwansik Yoon; Marcie L Vaughn; Timothy J Strelevitz; Robert S Foti
Flavin-containing monooxygenase activity in hepatocytes and microsomes: in vitro characterization and in vivo scaling of benzydamine clearance.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(10):1087-93.
2002: Michael B Fisher; David Jackson; Andreas Kaerner; Steven A Wrighton; Anthony G Borel
Characterization by liquid chromatography-nuclear magnetic resonance spectroscopy and liquid chromatography-mass spectrometry of two coupled oxidative-conjugative metabolic pathways for 7-ethoxycoumarin in human liver microsomes treated with alamethicin.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(3):270-5.
2001: Michael B Fisher; Mary F Paine; Timothy J Strelevitz; Steven A Wrighton
The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism.
Drug metabolism reviews 2001;33(3-4):273-97.
2000: Michael B Fisher; Mark R VandenBranden; K Findlay; B Burchell; K E Thummel; S D Hall; Steven A Wrighton
Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank.
Pharmacogenetics 2000;10(8):727-39.
2000: Mary F Paine; Michael B Fisher
Immunochemical identification of UGT isoforms in human small bowel and in caco-2 cell monolayers.
Biochemical and biophysical research communications 2000;273(3):1053-7.
2000: Michael B Fisher; Kristina M Campanale; Bradley L Ackermann; Mark R VandenBranden; Steven A Wrighton
In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(5):560-6.